ReviewInnovation (Cambridge (Mass.))2025
Emerging paradigms for target discovery of traditional medicines: A genome-wide pan-GPCR perspective.
Review in Innovation (Cambridge (Mass.)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A facile antibody-mediated CMC platform for targeted screening of CCR1 ligands fromJournal of pharmaceutical analysis · 2026Article
- Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).Acta pharmaceutica Sinica. B · 2026Article
- Engineering selective PI3KActa pharmaceutica Sinica. B · 2026Article
- Innovative strategies for anti-fibrotic drugs discovery from traditional Chinese medicine.Chinese herbal medicines · 2026Review
- Targeting tumor-associated G-protein coupled receptors: beyond single-axis inhibition toward multidimensional regulation.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Virtual and CMC-Based Screening Identified Reticuline, an Intermediate of BIA Biosynthesis, as a Potential Agonist of D5R.Molecules (Basel, Switzerland) · 2026Article
- Identification of Ellagic Acid as a Natural GPR35 Agonist for Ulcerative Colitis Therapy.Biomolecules · 2026Article
- Identification of Neferine as a DOR Agonist Activating GInternational journal of molecular sciences · 2026Article
- Comprehensive genomic identification and functional analysis ofChinese herbal medicines · 2026Article
- Genome-wide identification and characterization of methyltransferase involved in benzylisoquinoline alkaloids biosynthesis fromChinese herbal medicines · 2026Article
- Herbgenomics: Unraveling natural product biosynthesis in traditional Chinese medicine.Chinese herbal medicines · 2026Article
- Artificial intelligence-curated repository of gene-encoded natural diverse components from herbal medicines.Innovation (Cambridge (Mass.)) · 2025Article
- Omics-based profiling and therapeutic potential of natural components in pan-Shennongjia medicinal herbs.Chinese medicine · 2025Article
- Comparative analysis of Chinese classical prescriptions and global traditional polyherbal formulations: insights from the database of global polyherbal formulation (GPFD).Chinese medicine · 2025Article
- Transduction of Lentiviral Vectors andInternational journal of molecular sciences · 2025Article
- Alterations in Gene Expression and Alternative Splicing Induced by Plasmid-Mediated Overexpression of GFP andInternational journal of molecular sciences · 2025Article
- Unraveling the mysteries of the gut-kidney axis: the protective role of traditional Chinese medicine in chronic kidney disease.Frontiers in microbiology · 2025Review
- Analysis of maize PAL pan gene family and expression pattern under lepidopteran insect stress.Frontiers in plant science · 2025Article
- Drug repurposing in traditional Chinese medicine: from empirical wisdom to modern therapeutic strategies.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional medicines serve not only as an integral part of medical treatments prescribed by healthcare providers but also as a fundamental reservoir for novel molecular scaffolds. However, gaps remain in our understanding of the mechanisms underlying their activity. A superfamily of membrane proteins, G protein-coupled receptors (GPCRs), have been demonstrated to be potential targets for several compounds isolated from traditional medicines. Given that GPCRs serve as targets for approximately one-third of all marketed drugs, they may be compelling targets for repurposing traditional medicines. Despite this potential, research investigating their activity or potential ligands across GPCRome, the library of human GPCRs, is scarce. Drawing on the functional and structural knowledge presently available, this review contemplates prospective trends in GPCR drug discovery, proposes innovative strategies for investigating traditional medicines, and highlights ligand screening approaches for identifying novel drug-like molecules. To discover bioactive molecules from traditional medicines that either directly bind to GPCRs or indirectly modify their function, a genome-wide pan-GPCR drug discovery platform was designed for the identification of bioactive components and targets, and the evaluation of their pharmacological profiles. This platform aims to aid the exploration of all-sided relations between traditional medicines and GPCRome using advanced high-throughput screening techniques. We present various approaches used by many, including ourselves, to illuminate the previously unexplored aspects of traditional medicines and GPCRs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.